

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY DOCKET NO. 1000.06.	SERIAL NO. 10/082,521			
			JUL 18 2002 FILING 02/22/02	GROUP 1614			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		
<i>W</i>	A1 6,020,363	02/01/00	HIRANO, ET AL	541	1600/2900		
<i>RECEIVED JUL 25 2002 TECH CENTER 1600/2900</i>							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
B1						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>W</i>	C1	Teicher et al., "Optimal Scheduling of Interleukin-12 and Fractionated Radiation Therapy in the Murine Lewis Lung Carcinoma," <i>Radiation Oncology Investigations</i> , 6:71-80, 1998.					
<i>W</i>	C2	Kawai et al., "Enhancement of Anticancer Effects of Radiation and Conventional Anticancer Agents by a Quinolinone derivative, Vesnarinone: Studies on Human Gastric Cancer Tissues in Nude Mice, <i>Anticancer Res.</i> , 18:405-412, 1998.					
EXAMINER <i>Wayne Closson</i>			DATE CONSIDERED <i>May 8 3 2007</i>				

Form PTO-A820
(also form PTO-1449)


P09C/REV03

PATENT AND TRADEMARK OFFICE • U.S. DEPARTMENT OF COMMERCE

PAGE 1 OF 2

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

1000.06.

Application Number

09/794,417

Applicant(s)

TUMOR RADIOSENSITIZATION . . .

Filing Date

02/27/01

Group Art Unit

1614

*EXAMINER
INITIAL

OTHER DOCUMENTS (Include TRADEMARK, Title, Date, Pertinent Pages, Etc.)

Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Nat'l Cancer Inst., 87:581-586, 1995.

Gorski et al., "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation, Cancer Res., 59:3374-3378, 1999.

Norioka et al., "Interaction of Interleukin-1 and Interferon- γ on Fibroblast Growth Factor-Induced Angiogenesis, Jpn. J. cancer Res., 85:522-529, 1994.

Mauceri et al., "Combined effects of Angiostatin and Ionizing Radiation in Antitumor Therapy," Nature, 394:287-291, 1998.

Matsumoto et al. "Synthesis and Biological Evaluation of Cytogenin Derivatives," J. Antibiotics, 54:285-296, 2001.

Salloum et al., "NM-3, an Isocoumarin, Increases the Antitumor Effect of radiotherapy without Toxicity, Cancer Res., 60:6958-6963, 2000.

Agata et al., "NM-3, a Novel Angiogenesis Inhibitor, Potentiates Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells, Proceedings of the 2001 AACR-NCI-EORTC International Conference, p67 October 2001.

Yin et al., "The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) Propionic Acid (NM-3) Induces lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species," Mol. cancer Therapeutics, 1:43-48, 2001.

Reimer et al., "Antineoplastic Effects of Chemotherapeutic Agents are Potentiated by NM-3, an Inhibitor of Angiogenesis," Cancer Res., 62:789-795, 2002.

Nakashima, et al., "Inhibition of Angiogenesis by a New Isocoumarin NM-3," J. Antibiotics, 52:426-428, 2000.

Kumagi, et al., "Antitumor Activity of Cytogenin," J. Antibiotics, 48:175-178, 1995.

Oikawa, et al., "Effects of Cytogenin, a Novel Microbial Product, on Embryonic and Tumor Cell-Induced Angiogenic Responses In Vivo," Anticancer Res., 17:1881-1886, 1997.

EXAMINER

DATE CONSIDERED

May 3 2003

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.